UMANG VOHRA, Global Executive Director Managing Director and Global Executive Director
The next six months will be challenges, said the managing director of Cipla and Global Executive Director Umang Vohra, while the pharmaceutical industry faces several mobile parts, including rates in the United States.
“Every week or 10 days we are solving something new. It has become the way in the world. We were solving, first the rates … that began to calm down a little. Then we submitted to solve a possible Conhw Business linein a media interaction after the rooms.
“As more policy promulgations begin to stabilize, … the period after six months can be more certain than the next six months,” he added.
Cipla registered a net consolidated gain of ₹ 1,222 million rupees during the three months ending March 31, 2025, 30 percent more than during the same period last year. Registered an income of ₹ 6,730 million rupees, 9 percent more than last year. The company ended the year with a net gain of ₹ 5,273 million rupees, a 28 percent higher; and revenues of ₹ 27548 million rupees, 8 percent more than last year.
Vohra, however, did not give a guide for the present year, with the many “moving parts”, including the geopolitical situation and tariffs, he said. In the directive of the president of the United States, Trump on Monday, looking for price cuts in medicines or around 59 percent, Vohra said, although it was too early to evaluate the impact, the order was aimed at brand medications, he added. And as for generic drugs, he said, they were comparable to the US and possible in some cases. As for the expected American tariffs in a few days, Vohra indicated that it was unlikely that affordable generic medications will be affected, they thought that the company and industry were monitoring the situation that changes quickly.
Annual yield
When commenting on the company’s annual performance, Vohra had said in a statement: “In fiscal year 2000, we registered income growth or 8 percent during the past year with the Ebitda margin or 25.9 percent, driven by the mixture and other operations in a theria of health (year by year). Key therapes in the prescription of the brand continues to exceed the market, the project of commercial geniuses of the business of the business of the business route.
In an Africa, we recorded a solid growth of 12 % year -on -year in terms of dollar, driven by company’s performance in key markets. Emerging and Europe markets generated a substantial income growth of 15 percent year -on -year in the back of the deep market approach strategy. In the future, the approach will focus on the growth of our markets, building our flagship brands further, investing in future pipes and focusing on resolutions on the regulatory front. ”
Posted on May 13, 2025
